Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy

An analysis of data from the RADAR prostate radiotherapy trial

Noorazrul Azmie Yahya, Martin A. Ebert, Max Bulsara, Annette Haworth, Angel Kennedy, David J. Joseph, Jim W. Denham

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Abstract Purpose/objective To identify dosimetry, clinical factors and medication intake impacting urinary symptoms after prostate radiotherapy. Material and methods Data describing clinical factors and bladder dosimetry (reduced with principal component (PC) analysis) for 754 patients treated with external beam radiotherapy accrued by TROG 03.04 RADAR prostate radiotherapy trial were available for analysis. Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade ≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36- and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade ≥2. Impact of factors was assessed using multivariate logistic regression models with correction for over-optimism. Results Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.

Original languageEnglish
Article number6495
Pages (from-to)112-118
Number of pages7
JournalRadiotherapy and Oncology
Volume116
Issue number1
DOIs
Publication statusPublished - 1 Jul 2015

Fingerprint

Prostate
Radiotherapy
Incidence
Logistic Models
Dysuria
Hematuria
Principal Component Analysis
Type 2 Diabetes Mellitus
Urinary Bladder
Anti-Inflammatory Agents
Smoking
Pharmaceutical Preparations

Keywords

  • Prostate cancer
  • Radiotherapy
  • Urinary symptoms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy : An analysis of data from the RADAR prostate radiotherapy trial. / Yahya, Noorazrul Azmie; Ebert, Martin A.; Bulsara, Max; Haworth, Annette; Kennedy, Angel; Joseph, David J.; Denham, Jim W.

In: Radiotherapy and Oncology, Vol. 116, No. 1, 6495, 01.07.2015, p. 112-118.

Research output: Contribution to journalArticle

Yahya, Noorazrul Azmie ; Ebert, Martin A. ; Bulsara, Max ; Haworth, Annette ; Kennedy, Angel ; Joseph, David J. ; Denham, Jim W. / Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy : An analysis of data from the RADAR prostate radiotherapy trial. In: Radiotherapy and Oncology. 2015 ; Vol. 116, No. 1. pp. 112-118.
@article{7b1d02d79fd34434862f736bc9f4fecf,
title = "Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial",
abstract = "Abstract Purpose/objective To identify dosimetry, clinical factors and medication intake impacting urinary symptoms after prostate radiotherapy. Material and methods Data describing clinical factors and bladder dosimetry (reduced with principal component (PC) analysis) for 754 patients treated with external beam radiotherapy accrued by TROG 03.04 RADAR prostate radiotherapy trial were available for analysis. Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade ≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36- and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade ≥2. Impact of factors was assessed using multivariate logistic regression models with correction for over-optimism. Results Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.",
keywords = "Prostate cancer, Radiotherapy, Urinary symptoms",
author = "Yahya, {Noorazrul Azmie} and Ebert, {Martin A.} and Max Bulsara and Annette Haworth and Angel Kennedy and Joseph, {David J.} and Denham, {Jim W.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.radonc.2015.06.011",
language = "English",
volume = "116",
pages = "112--118",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy

T2 - An analysis of data from the RADAR prostate radiotherapy trial

AU - Yahya, Noorazrul Azmie

AU - Ebert, Martin A.

AU - Bulsara, Max

AU - Haworth, Annette

AU - Kennedy, Angel

AU - Joseph, David J.

AU - Denham, Jim W.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Abstract Purpose/objective To identify dosimetry, clinical factors and medication intake impacting urinary symptoms after prostate radiotherapy. Material and methods Data describing clinical factors and bladder dosimetry (reduced with principal component (PC) analysis) for 754 patients treated with external beam radiotherapy accrued by TROG 03.04 RADAR prostate radiotherapy trial were available for analysis. Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade ≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36- and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade ≥2. Impact of factors was assessed using multivariate logistic regression models with correction for over-optimism. Results Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.

AB - Abstract Purpose/objective To identify dosimetry, clinical factors and medication intake impacting urinary symptoms after prostate radiotherapy. Material and methods Data describing clinical factors and bladder dosimetry (reduced with principal component (PC) analysis) for 754 patients treated with external beam radiotherapy accrued by TROG 03.04 RADAR prostate radiotherapy trial were available for analysis. Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade ≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36- and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade ≥2. Impact of factors was assessed using multivariate logistic regression models with correction for over-optimism. Results Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.

KW - Prostate cancer

KW - Radiotherapy

KW - Urinary symptoms

UR - http://www.scopus.com/inward/record.url?scp=84938963266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938963266&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.06.011

DO - 10.1016/j.radonc.2015.06.011

M3 - Article

VL - 116

SP - 112

EP - 118

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

M1 - 6495

ER -